Oramed Pharmaceuticals Inc.
ORMP
$2.33
$0.031.30%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -176.40% | -508.91% | 871.52% | 145.24% | 256.10% |
| Total Depreciation and Amortization | -41.51% | -3.70% | 3.85% | 51.35% | 211.76% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 157.35% | 1,551.98% | -634.32% | -77.60% | -812.05% |
| Change in Net Operating Assets | 103.32% | -10.40% | 167.22% | 23.28% | 70.88% |
| Cash from Operations | -34.77% | -923.20% | 178.82% | 73.40% | 82.41% |
| Capital Expenditure | -266.67% | 84.38% | 100.00% | 98.99% | 99.03% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -48.55% | 54.38% | 744.35% | 330.70% | 159.88% |
| Cash from Investing | -48.58% | 54.39% | 743.47% | 327.21% | 166.40% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 100.00% | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -64,450.00% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 95.22% | -101.73% | -- | -881.89% | -698.80% |
| Foreign Exchange rate Adjustments | -125.00% | 109.68% | -157.14% | 97.37% | 107.62% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 243.35% | -3,183.22% | 481.71% | 158.20% | -50.65% |